Home/Filings/4/0000899243-21-005458
4//SEC Filing

Smith W Bradford 4

Accession 0000899243-21-005458

CIK 0001661998other

Filed

Feb 8, 7:00 PM ET

Accepted

Feb 9, 4:22 PM ET

Size

14.1 KB

Accession

0000899243-21-005458

Insider Transaction Report

Form 4
Period: 2021-02-05
Smith W Bradford
CFO, Treasurer & Secretary
Transactions
  • Exercise/Conversion

    Common Stock

    2021-02-08$0.64/sh+13,500$8,64013,500 total
  • Award

    Restricted Stock Units

    2021-02-05+20,00020,000 total
    Common Stock (20,000 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-02-0813,500101,904 total
    Exercise: $0.64Exp: 2027-04-05Common Stock (13,500 underlying)
  • Sale

    Common Stock

    2021-02-08$14.25/sh13,500$192,4250 total
  • Award

    Employee Stock Option (Right to Buy)

    2021-02-05+122,000122,000 total
    Exercise: $13.78Exp: 2031-02-05Common Stock (122,000 underlying)
Footnotes (6)
  • [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2020.
  • [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $14.00 to $14.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F5]The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024.
  • [F6]The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017.

Issuer

Homology Medicines, Inc.

CIK 0001661998

Entity typeother

Related Parties

1
  • filerCIK 0001317678

Filing Metadata

Form type
4
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 4:22 PM ET
Size
14.1 KB